Top news of the week: 13.10.2021.
Startups
Backed with $500 million, a startup aims to rethink psychiatric drug development
Neumora, a roll-up of assets from several biotech firms and the drug giant Amgen, is seeking to "apply precision medicine" to CNS diseases.
Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a ...
Josh Bekenstein, co-chair of the investment firm Bain Capital, heads the board of trustees at Dana-Farber Cancer Institute.
Access to trustee investments and market expertise can help the hospital. But this practice creates potential conflicts of interest at the highest level of an institution and worries about ...
MIT is a global powerhouse for climate change innovation, pumping out world-class talent in disciplines crucial for climate technology companies.
A new generation of innovators in Massachusetts has emerged, aiming their moonshot ideas at a climate crisis that has only gotten worse and made their task all the more urgent.
Pasito wins $25,000 in Latinx Pitch Competition
Pasito, a New York City-based financial wellness startup won $25,000 by out-pitching nine other companies during VCFamilia’s inaugural Latinx Pitch Competition, held as a virtual event on ...
The Inside Story Of How SoftBank-Backed Zymergen Imploded Four Months After Its $3 Billion IPO
Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding. By August, its CEO was out and the synthetic biology company wouldn’t say when ...
A new startup created by one of biotech's biggest VCs shows you need to go big to treat brain disorders
Arch Venture Partners, a top biotech investor, has retooled and relaunched one of its startups as a megabiotech.
Armed with half a billion dollars, a startup aims to change how brain drugs are made
Neumora Therapeutics launched Thursday with a $100 million investment from Amgen and another $400 million from a long list of venture capital firms, including Arch, which is taking another ...